Recombinant DNA Technology Market Research Report - Forecast to 2030

Recombinant DNA Technology Market Information By Product (Medical and Non-Medical), By Component (Expression System and Cloning Vector), By Application (Food & Agriculture, and Health & Disease), By End User (Biotechnology Companies and Pharmaceuticals), and Region (North America, Europe, Asia-Pacific, and the Rest of the World)‚ÄĒForecast till 2030

ID: MRFR/LS/4389-HCR | February 2023 | Region: Global | 100 Pages         

Recombinant DNA Technology Market Speak to Analyst Request a Free Sample

Recombinant DNA Technology Market

Recombinant DNA Technology Market is expected to grow at CAGR of 4.9% to reach USD 1.06 trillion during the forecasted period 2022-2030.

By Product Medical Non-Medical
By Component Expression System Cloning Vector
By Application Food & Agriculture Health & Disease
By End-User Biotechnology Companies Pharmaceuticals
Key Players
Companies Profiled   Amgen Inc. (U.S.)    F. Hoffmann-La Roche Ltd (Switzerland)   Profacgen (U.S.)   Novartis AG (Switzerland)   Novo Nordisk A/S (Denmark   Genscript Biotech (U.S.)   Pfizer Inc. (U.S.)   Sanofi S.A. (France)   Eli Lilly and Company (U.S.)   Biogen Inc. (U.S.)
Market Driving Forces   Gowing adoption of genetically modified biopesticides and crops   Increasing adoption of recombinant DNA technology
Request a Free Sample

Global Recombinant DNA Technology Market Research (MRFR Insights)

The Recombinant DNA Technology Market is expected to reach USD 1.06 trillion by 2030 at 4.9% CAGR during the forecast period 2022-2030. Scientists now have unprecedented control over genetic material thanks to recombinant DNA (rDNA) technology. This has increased its use in a wide range of traditional and unconventional applications. This field has made remarkable progress in the creation of recombinant medications and therapies without the use of human donors in recent years. ‚ÄčThe commercial success of genetically modified insulin for diabetes therapy is a typical example of this feat. The biotech and pharmaceutical industries are engaged in interpreting the potential of rDNA approaches in many parts of disease management. This is primarily to battle the rising burden of chronic diseases and to keep up with the growing demand for treatments. For instance, in February 2022, VBI Vaccines Inc. obtained good feedback from the European Medicines Agency's Committee for Medicinal Product Use. This opinion was connected to the 3-antigen hepatitis B (HBV) vaccine, PreHevbri, for establishing vaccination to protect against infection caused by the hepatitis B virus in adults. Hepatitis B remains a public health issue in Europe; consequently, this favorable opinion established a meaningful choice for health providers in safeguarding patients from the disease. ‚Äč

COVID-19 Impact Analysis

The COVID-19 pandemic had a favorable impact on the ¬†market, owing to the unique recombinant technologies used to create the COVID-19 vaccine. According to a National Center for Biotechnology Information article, novel recombinant technologies will be used in developing the COVID-19 vaccine in November 2020, in addition, to live vector and inactivated viruses. The benefits of recombinant vaccinations include increased response predictability and efficacy. ‚Äč

Recombinant DNA Technology Market Dynamics

Remarkable advancements in the sector to treat life-threatening human disorders such as infectious diseases, diabetes, and cancer are some of the major drivers influencing market growth. Recombinant technology advancements have aided in the development of long-acting therapeutic proteins for medication development, the introduction of gene therapy, and the development of innovative molecular medicine. Positive impact on genetic disease treatment and growing innovations will likely drive market expansion during the forecast period. ‚ÄčLeading biopharmaceutical businesses and research institutes strategically work with key manufacturers to create novel therapies based on recombinant DNA technology. Such collaborations are expected to drive worldwide market growth throughout the forecast period.

Market Drivers

  • Increased strategic collaborations among industry participants

Increasing strategic collaborations by leading market players to advance recombinant DNA technology are projected to fuel market expansion over the forecast period. Major market participants collaborate strategically with major biopharmaceutical companies and research institutes to develop innovative therapies based on recombinant DNA technologies. Such market-wide strategic collaborations are projected to foster the expansion of the  market shortly. For instance, Sanofi Pasteur, the vaccines division of the French multinational pharmaceutical company Sanofi, acquired Protein Sciences Corporation, a biotech company based in Meriden, Connecticut, in August 2017 to add a promising product to its vaccine portfolio - Flublok (Influenza Vaccine), the only FDA-approved recombinant protein-based influenza vaccine.

Market Restraints:

  • High price and side effects associated with gene treatments

The high expense of gene therapy and adverse effects such as Cytokine Release Syndrome (CRS) or Neurological Toxicities are inhibiting market expansion. Additionally, scientific, regulatory, and ethical constraints linked with gene therapy are projected to limit market expansion during the projection period.

Market Opportunities:

  • Opportunity in product development

Many additional businesses benefit from genetically modified organisms (GMO) research, such as microorganisms that are considered clean fuel generators and bio degraders. Genetically engineered vaccinations are produced to cure numerous diseases in humans and plants. By changing microbes, animals, and plants to provide medically valuable compounds, recombinant DNA technology has created various potential opportunities and prospects for generating a wide range of therapeutic items with immediate effects in medical genetics and biomedicine.

Recombinant DNA Technology Market Segmentation

Product Insights

The market segment of recombinant DNA technology, by product, is medical and non-medical. The medical segment dominated the market in 2021, and this trend is expected to continue at the highest CAGR over the forecast period. rDNA technology has changed the medical industry and has an ever-increasing impact on clinical medicine. It has facilitated illness treatment by inserting fresh genes in place of damaged & sick genes. Growth in the medical segment is expected to be also driven by advances in genetic engineering and process development. The success of GM crops is driving the non-medical component of this business.

Component Insights

The market segment of recombinant DNA technology, by component, is expression system and cloning vector. The largest part was acquired by expression systems, owing to continuous improvements for efficient protein expression and large-scale protein isolation. Mammalian, bacterial, insect, and yeast expression systems are the most commonly employed. The creation of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed significantly to the mammalian expression system market share.

Application Insights

By application, the market is segmented into food & agriculture and health & disease. The health & disease application has accounted for the majority of the share in the recombinant DNA technology market growth in 2021. This high proportion can be attributable to a diverse variety of recombinant products for human illness treatment, including medicines, vaccines, and enzyme replacements. With the increasing burden of crop development and the resulting stress on farmers to satisfy customer expectations, this technology has steadily grown as a panacea for tackling these agriculture sector concerns.

End User Insights

By end user, the market is segmented into biotechnology companies and pharmaceuticals. The biotechnology companies category dominated the market in 2021. With demand growing in industries including pharmaceutical, healthcare, medicine, genetic engineering, animal husbandry, agriculture, etc., biotechnology companies are burgeoning employment options.

Global Recombinant DNA Technology Market Share, by Region, 2021 (%)
Recombinant DNA Technology Market Share, by Region, 2021
Recombinant DNA Technology Market Overview, by Region

By Region, the  market of recombinant DNA technology has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Asia-Pacific will exhibit the highest CAGR during the forecast period.

North America

In 2021, the North American region held the largest market share. The greatest proportion of the North American area can be attributable to the fact that the United States is home to many biopharmaceutical manufacturing participants. Furthermore, the availability of strong regulatory organizations to monitor the numerous ethical and scientific concerns associated with using technology has fueled regional progress.


The presence of low-cost manufacturing centers in Asian nations such as China has piqued the interest of multinational companies looking to relocate their operations to this region. Furthermore, Japan is one of the world's tops per capita importers of food and feed, developed with current biotechnology methods. Japan's GE agricultural regulating regime is becoming better. Furthermore, there are no significant trade barriers in Japan to impede the export of GE items from Western countries. As a result, Asia-Pacific is predicted to be the region's fastest-growing market in the forecast period.

 Recombinant DNA Technology Market Competitive Landscape

The market includes tier-1, tier-2, and local players. The tier-1 and tier-2 players have  reach with diverse product portfolios. Companies such as Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), and Novartis AG (Switzerland) dominate the  market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are concentrating on supporting research and development. Furthermore, they embrace strategic growth initiatives, such as development, product introduction, joint ventures, and partnerships, to strengthen their market position and capture an extensive customer base. For instance, VBI Vaccines Inc. approved PreHevbrio (Recombinant Hepatitis B Vaccine) in the United States in March 2022 to prevent infection caused by hepatitis B virus (HBV) in adults aged 18 and older. Furthermore, the release of the vaccine can potentially increase immunization rates with US health professionals' help while protecting adult patients against HBV.

Prominent players in the  recombinant DNA technology market research include Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), and Biogen Inc. (U.S.), among others.

Scope of the  Recombinant DNA Technology Market Report

Product Outlook

  • Medical

  • Non-Medical

Component Outlook

  • Expression System

  • Cloning Vector

Application Outlook

  • Food & Agriculture

  • Health & Disease

End User Outlook

  • Biotechnology Companies

  • Pharmaceuticals

Region Outlook

  • North America

    • US

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia and New Zealand

    • Rest of Asia-Pacific

  • Rest of the World

    • South America

    • Middle East

    • Africa

Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

Recombinant DNA Technology Market Forecast & Size:

To identify and estimate the market size for the  recombinant DNA technology segmented by product, component, application, and end-user by value (in US dollars). Also, to understand the consumption/ demand created by consumers in the market of recombinant DNA technology forecast between 2022 and 2030.

Market Landscape and Trends:

To identify and infer the drivers, restraints, opportunities, and challenges in the  recombinant DNA technology market growth

Market Influencing Factors:

To find out the factors which are affecting the  market size of recombinant DNA technology among consumers

Impact of COVID-19:

To identify and understand the various factors involved in the market affected by the pandemic

Company Profiling:

To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Intended Audience

  • Producers

  • Raw material suppliers

  • Retailers, wholesalers, and distributors

  • Governments, associations, and industrial bodies

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 1.06 Trillion
  CAGR   4.9%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Trillion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Component, Application, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  Key Vendors   Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland)
  Key Market Opportunities   Opportunity in product development
  Key Market Drivers   Increased R&D initiatives and strategic collaborations among industry participants

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The  recombinant DNA technology market forecast period is 2022-2030

The market is expected to register a CAGR of ~4.9% over the next 10 years, according to the  recombinant DNA technology market research.

Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.

Asia-Pacific is expected to register the highest CAGR during 2022-2030

North America held the largest share in 2021

The market size is expected to be USD 1.06 trillion by 2030.

Amgen Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), and Biogen Inc. (U.S.) are the major companies operating in the market.